Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment

Hannah Cohen; Beverley J. Hunt; Maria Efthymiou; Ian J. Mackie; Munther Khamashta; David A. Isenberg; RAPS Trial Investigators

doi:10.1007/s11926-017-0675-3

Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment

Hannah Cohen^*, Beverley J. Hunt, Maria Efthymiou, Ian J. Mackie, Munther Khamashta, David A. Isenberg, RAPS Trial Investigators

^*Corresponding author for this work

UCL University College London

Research output: Contribution to journal › Letter › peer-review

5 Citations (Scopus)

160 Downloads (Pure)

Abstract

We respond to comments by Dufrost et al. about the RAPS trial, in particular, showing that the trial did achieve its target sample size; pointing out that thrombin potential is not synonymous with overall thrombin generation; confirming that overall, no increased thrombotic risk was evident comparing rivaroxaban with warfarin; and that high-risk patients (28% were triple positive, representative of patients with venous thromboembolism requiring standard-intensity anticoagulation) were included; and clarifying our rationale for using a laboratory surrogate primary outcome measure instead of a clinical one.

Original language	English
Article number	50
Journal	Current Rheumatology Reports
Volume	19
Issue number	8
Early online date	20 Jul 2017
DOIs	https://doi.org/10.1007/s11926-017-0675-3
Publication status	Published - Aug 2017

Keywords

Antiphospholipid syndrome
Rivaroxaban
Thrombin generation
Venous thromboembolism
Warfarin

Access to Document

10.1007/s11926-017-0675-3Licence: CC BY

Direct Oral Anticoagulants Use_COHEN_Publishedonline20July2017_GOLD VoR (CC BY)Final published version, 286 KBLicence: CC BY

Cite this

Cohen, H., Hunt, B. J., Efthymiou, M., Mackie, I. J., Khamashta, M., Isenberg, D. A., & RAPS Trial Investigators (2017). Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment. Current Rheumatology Reports, 19(8), Article 50. https://doi.org/10.1007/s11926-017-0675-3

@article{708d3b32b2204616b501d1dee7d40e28,

title = "Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment",

abstract = "We respond to comments by Dufrost et al. about the RAPS trial, in particular, showing that the trial did achieve its target sample size; pointing out that thrombin potential is not synonymous with overall thrombin generation; confirming that overall, no increased thrombotic risk was evident comparing rivaroxaban with warfarin; and that high-risk patients (28% were triple positive, representative of patients with venous thromboembolism requiring standard-intensity anticoagulation) were included; and clarifying our rationale for using a laboratory surrogate primary outcome measure instead of a clinical one.",

keywords = "Antiphospholipid syndrome, Rivaroxaban, Thrombin generation, Venous thromboembolism, Warfarin",

author = "Hannah Cohen and Hunt, {Beverley J.} and Maria Efthymiou and Mackie, {Ian J.} and Munther Khamashta and Isenberg, {David A.} and {RAPS Trial Investigators}",

year = "2017",

month = aug,

doi = "10.1007/s11926-017-0675-3",

language = "English",

volume = "19",

journal = "Current Rheumatology Reports",

issn = "1523-3774",

publisher = "Current Science, Inc.",

number = "8",

}

Cohen, H, Hunt, BJ, Efthymiou, M, Mackie, IJ, Khamashta, M, Isenberg, DA & RAPS Trial Investigators 2017, 'Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment', Current Rheumatology Reports, vol. 19, no. 8, 50. https://doi.org/10.1007/s11926-017-0675-3

TY - JOUR

T1 - Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature

T2 - Comment

AU - Cohen, Hannah

AU - Hunt, Beverley J.

AU - Efthymiou, Maria

AU - Mackie, Ian J.

AU - Khamashta, Munther

AU - Isenberg, David A.

AU - RAPS Trial Investigators

PY - 2017/8

Y1 - 2017/8

N2 - We respond to comments by Dufrost et al. about the RAPS trial, in particular, showing that the trial did achieve its target sample size; pointing out that thrombin potential is not synonymous with overall thrombin generation; confirming that overall, no increased thrombotic risk was evident comparing rivaroxaban with warfarin; and that high-risk patients (28% were triple positive, representative of patients with venous thromboembolism requiring standard-intensity anticoagulation) were included; and clarifying our rationale for using a laboratory surrogate primary outcome measure instead of a clinical one.

AB - We respond to comments by Dufrost et al. about the RAPS trial, in particular, showing that the trial did achieve its target sample size; pointing out that thrombin potential is not synonymous with overall thrombin generation; confirming that overall, no increased thrombotic risk was evident comparing rivaroxaban with warfarin; and that high-risk patients (28% were triple positive, representative of patients with venous thromboembolism requiring standard-intensity anticoagulation) were included; and clarifying our rationale for using a laboratory surrogate primary outcome measure instead of a clinical one.

KW - Antiphospholipid syndrome

KW - Rivaroxaban

KW - Thrombin generation

KW - Venous thromboembolism

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=85025095227&partnerID=8YFLogxK

U2 - 10.1007/s11926-017-0675-3

DO - 10.1007/s11926-017-0675-3

M3 - Letter

AN - SCOPUS:85025095227

SN - 1523-3774

VL - 19

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

IS - 8

M1 - 50

ER -

Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this